Related Experiment Video
Updated: May 9, 2026
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Efficacy and tolerability of compounded bioidentical hormone replacement therapy
Kristy A Vigesaa1, Nathan P Downhour, Michelle A Chui
1Banner Baywood Medical Center, Mesa, Arizona.
International Journal of Pharmaceutical Compounding
|August 9, 2013
Summary
Compounded bioidentical hormone replacement therapy (BHRT) effectively relieved menopausal symptoms and was well tolerated by women. BHRT demonstrated fewer side effects compared to commercially available hormone products.
Area of Science:
- Endocrinology
- Women's Health
- Pharmacology
Background:
- Menopausal hormone therapy is widely used for symptom management.
- Compounded bioidentical hormone replacement therapy (BHRT) offers personalized treatment options.
- Limited comparative data exists on the efficacy and tolerability of BHRT versus commercial products.
Purpose of the Study:
- To assess symptom relief and tolerability of compounded BHRT in menopausal women.
- To compare compounded BHRT with previously used commercial hormone therapies.
- To evaluate the impact of compounded BHRT on the severity of menopausal symptoms.
Main Methods:
- A six-week survey study involving 78 women using compounded BHRT.
- Survey instrument assessed symptom outcomes and side effects.
- Comparison of compounded BHRT to prior use of commercially available hormone products.
Main Results:
- 71.8% of women reported better relief of menopausal symptoms with compounded BHRT.
- 57.7% of women experienced fewer side effects compared to commercial products.
- Moderate-to-severe menopausal symptoms decreased significantly, from 52-70% to 4-20%.
Conclusions:
- Compounded bioidentical hormone replacement therapy is effective in relieving menopausal symptoms.
- Compounded BHRT is generally well-tolerated by women.
- Compounded BHRT shows a favorable side effect profile compared to commercial hormone therapies.
Related Concept Videos
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.